• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Warby Parker Partners with Google To Develop Intelligent Eyewear

    5/20/25 1:58:00 PM ET
    $WRBY
    Ophthalmic Goods
    Health Care
    Get the next $WRBY alert in real time by email

    AI-Powered Glasses Will Be Designed for All-Day Wear

    Announcement Marks First Eyewear Partnership for Android XR

    Google Commits Up to $150M, Including an Equity Investment in Warby Parker, as Part of Long-Term Commitment to Partnership

    Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced a partnership with Google to develop AI-powered glasses intended for all-day wear. The partnership will combine Warby Parker's signature approach to eyewear design with Google's industry-leading technology ecosystem, bringing the next generation of computing to a new form factor: glasses.

    "Since our launch we've set out to transform the optical industry by leveraging pioneering technology to design better products and experiences—and over the past 15 years, we've done just that," said Co-Founder and Co-CEO Dave Gilboa. "Looking ahead, we believe multimodal AI is perfectly suited for glasses, enabling real-time context and intelligence to augment a wearer's surroundings as they move through the world. We couldn't be more excited to be partnering with Google to bring together the best of AI and the best of eyewear."

    "We're excited to work with Google to develop intelligent eyewear that will enhance our everyday lives. The eyewear we wear and the technology we use are core parts of our identity and our daily experience. Our teams share a commitment to leverage design, utility, and innovation to build products to help customers in every aspect of life," added Co-Founder and Co-CEO Neil Blumenthal.

    The companies are working closely on the development of future smart glasses and intend to launch a series of products over time. The partners' first line of intelligent eyewear, planned to launch after 2025, will incorporate multimodal AI with prescription and non-prescription lenses.

    "Warby Parker's optical expertise, omnichannel approach, and history of leveraging technology to create beautifully designed products and exceptional customer experiences make them the perfect partner to co-create and launch this next generation of smart glasses on the Android XR platform," shared Shahram Izadi, GM and VP of XR at Google.

    As part of this collaboration, Google has committed up to $75 million for Warby Parker's product development and commercialization costs. In addition, Google has committed to investing up to $75 million in Warby Parker, at Warby Parker's option and subject to reaching certain collaboration milestones.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, expectations of future operating results or financial performance, including expectations regarding achieving profitability and growth, delivering stakeholder value, growing market share; management's plans, priorities, initiatives and strategies; expectations regarding growth of our business; expectations regarding investments in the Company and our ability to achieve milestones; expectations regarding the viability and success of new products and the success of partnerships and the ability to effectively collaborate. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "toward," "will," or "would," or the negative of these words or other similar terms or expressions. You should not put undue reliance on any forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved, if at all.

    Forward-looking statements are based on information available at the time those statements are made and are based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control, that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially from those anticipated or implied in the forward-looking statements. These risks and uncertainties include our ability to manage our future growth effectively; our expectations regarding cost of goods sold, gross margin, channel mix, customer mix, and selling, general, and administrative expenses; increases in component and shipping costs and changes in supply chain; changes to U.S. or other countries' trade policies and tariff and import/export regulations; our reliance on our information technology systems and enterprise resource planning systems for our business to effectively operate and safeguard confidential information; our ability to invest in and incorporate new technologies into our products and services; risks related to our use of artificial intelligence; our ability to engage our existing customers and obtain new customers; our ability to expand in-network access with insurance providers; planned new retail stores in 2025 and going forward; an overall decline in the health of the economy and other factors impacting consumer spending, such as recessionary conditions, inflation, infectious diseases, government instability, and geopolitical unrest; our ability to compete successfully; our ability to manage our inventory balances and shrinkage; the growth of our brand awareness; our ability to recruit and retain optometrists, opticians, and other vision care professionals; the effects of seasonal trends on our results of operations; our ability to stay in compliance with extensive laws and regulations that apply to our business and operations; our ability to adequately maintain and protect our intellectual property and proprietary rights and license necessary third-party intellectual property and proprietary rights; our reliance on third parties for our products, operation and infrastructure; our duties related to being a public benefit corporation; the ability of our Co-Founders and Co-CEOs to exercise significant influence over all matters submitted to stockholders for approval; the effect of our multi-class structure on the trading price of our Class A common stock; our ability to achieve milestones necessary for Google's equity investment into the Company and Google's contribution to product development and commercialization costs; our ability to collaborate with partners with successful results; our ability to recognize the anticipated benefits from the partnership with Google; and the increased expenses associated with being a public company. Additional information regarding these and other risks and uncertainties that could cause actual results to differ materially from the Company's expectations is included in our most recent reports filed with the SEC on Form 10-K, Form 10-Q and Form 8-K. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

    Additional information regarding these and other factors that could affect the Company's results is included in the Company's SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov. Information contained on, or that is referenced or can be accessed through, our website does not constitute part of this document and inclusions of any website addresses herein are inactive textual references only.

    About Warby Parker

    Warby Parker (NYSE:WRBY) was founded in 2010 with a mission to inspire and impact the world with vision, purpose, and style—without charging a premium for it. Headquartered in New York City, the co-founder-led lifestyle brand pioneers ideas, designs products, and develops technologies that help people see, from designer-quality prescription glasses (starting at $95) and contacts, to eye exams and vision tests available online and in our 287 retail stores across the U.S. and Canada.

    Warby Parker aims to demonstrate that businesses can scale, do well, and do good in the world. Ultimately, the Company believes in vision for all, which is why for every pair of glasses or sunglasses sold, it distributes a pair to someone in need through its Buy a Pair, Give a Pair program. To date, Warby Parker has worked alongside its nonprofit partners to distribute more than 15 million glasses to people in need.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250520232084/en/

    Investor Relations:

    Jaclyn Berkley

    [email protected]



    Media:

    Ava Rojo

    [email protected]

    Get the next $WRBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WRBY

    DatePrice TargetRatingAnalyst
    4/30/2025$17.00Sell → Neutral
    Citigroup
    4/17/2025$27.00Hold → Buy
    Loop Capital
    2/28/2025$28.00 → $30.00Outperform
    Telsey Advisory Group
    2/25/2025$26.00Neutral
    ROTH MKM
    2/5/2025$19.00 → $23.00Neutral → Sell
    Citigroup
    1/17/2025$23.00Outperform → In-line
    Evercore ISI
    11/19/2024$22.00 → $26.00Outperform
    Telsey Advisory Group
    11/8/2024$19.00 → $22.00Outperform
    Telsey Advisory Group
    More analyst ratings

    $WRBY
    Leadership Updates

    Live Leadership Updates

    See more
    • Warby Parker appoints Ronald A. Williams as Lead Director and welcomes Bradley E. Singer to Board of Directors

      Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company") announced today the appointment of Ron Williams as Lead Director. "Ron's deep expertise in transformational leadership is helping Warby Parker lead the way in making the optical industry more customer and patient friendly. Our shareholders and our team are lucky to have such an exceptional and experienced leader as our first Lead Director," said Neil Blumenthal, co-Founder and co-CEO. The Company has also appointed a new independent director, Brad Singer, to its board of directors. Mr. Singer's appointment is effective today, August 1, 2024. "Brad brings a wealth of experience as a dynamic operator and investor," said Dav

      8/1/24 4:15:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cutler Joel E disposed of 5,656,571 shares (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      3/18/25 9:52:05 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Chief Financial Officer Miller Steven Clive sold $274,808 worth of shares (11,684 units at $23.52), was granted 15,128 shares, covered exercise/tax liability with 6,321 shares and converted options into 27,731 shares, increasing direct ownership by 14% to 204,727 units (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      3/6/25 6:02:10 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Co-Chief Executive Officer Gilboa David Abraham converted options into 3,271 shares, sold $4,772,513 worth of shares (202,968 units at $23.51), was granted 23,250 shares, covered exercise/tax liability with 12,858 shares and converted options into 201,088 shares, increasing direct ownership by 96% to 24,089 units (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      3/5/25 9:57:41 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Financials

    Live finance-specific insights

    See more
    • Warby Parker Announces First Quarter 2025 Results

      Net revenue increased 12% year over year to $224 million Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. "Our team delivered a strong start to 2025. We opened 11 net new stores, exceeded profitability expectations, drove the highest e-commerce growth we've seen since 2021, and delivered our seventh consecutive quarter of accelerating active customer growth," shared Co-Founder and Co-CEO Neil Blumenthal. "Looking to the rest of the year, we'll leverage our diversified suppl

      5/8/25 6:45:00 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker to Announce First Quarter 2025 Financial Results on May 8, 2025

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the first quarter ended March 31, 2025 will be released before market open on May 8, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 020310. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where presentation

      4/17/25 4:05:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Announces Fourth Quarter and Full Year 2024 Results

      Q4 net revenue increased 17.8% year over year; 2024 net revenue increased 15.2% year over year Active Customers increased 7.8% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the fourth quarter and full year ended December 31, 2024. "Our strong 2024 results highlight the power of Warby Parker's brand and unmatched value proposition combined with our team's high-quality execution. We delivered on our ambitious goals to accelerate revenue growth, customer growth and glasses growth, all while maintaining operational discipline and expanding p

      2/27/25 6:45:00 AM ET
      $TGT
      $WRBY
      Department/Specialty Retail Stores
      Consumer Discretionary
      Ophthalmic Goods
      Health Care

    $WRBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/14/24 5:08:23 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/14/24 1:30:16 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Warby Parker Inc.

      SC 13G/A - Warby Parker Inc. (0001504776) (Subject)

      11/12/24 10:40:28 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    SEC Filings

    See more
    • Warby Parker Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

      8-K - Warby Parker Inc. (0001504776) (Filer)

      5/20/25 2:24:32 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Warby Parker Inc.

      SCHEDULE 13G/A - Warby Parker Inc. (0001504776) (Subject)

      5/12/25 10:20:43 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by Warby Parker Inc.

      10-Q - Warby Parker Inc. (0001504776) (Filer)

      5/8/25 5:10:13 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Singer Bradley E bought $965,750 worth of shares (75,000 units at $12.88) (SEC Form 4)

      4 - Warby Parker Inc. (0001504776) (Issuer)

      8/14/24 4:52:02 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Warby Parker upgraded by Citigroup with a new price target

      Citigroup upgraded Warby Parker from Sell to Neutral and set a new price target of $17.00

      4/30/25 1:18:55 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker upgraded by Loop Capital with a new price target

      Loop Capital upgraded Warby Parker from Hold to Buy and set a new price target of $27.00

      4/17/25 8:27:42 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Telsey Advisory Group reiterated coverage on Warby Parker with a new price target

      Telsey Advisory Group reiterated coverage of Warby Parker with a rating of Outperform and set a new price target of $30.00 from $28.00 previously

      2/28/25 8:48:26 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care

    $WRBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Warby Parker Partners with Google To Develop Intelligent Eyewear

      AI-Powered Glasses Will Be Designed for All-Day Wear Announcement Marks First Eyewear Partnership for Android XR Google Commits Up to $150M, Including an Equity Investment in Warby Parker, as Part of Long-Term Commitment to Partnership Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced a partnership with Google to develop AI-powered glasses intended for all-day wear. The partnership will combine Warby Parker's signature approach to eyewear design with Google's industry-leading technology ecosystem, bringing the next generation of computing to a new form factor: glasses. "Since our launch we've set out to transfo

      5/20/25 1:58:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker Announces First Quarter 2025 Results

      Net revenue increased 12% year over year to $224 million Active Customers increased 9% on a trailing 12-month basis Warby Parker Inc. (NYSE:WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the first quarter ended March 31, 2025. "Our team delivered a strong start to 2025. We opened 11 net new stores, exceeded profitability expectations, drove the highest e-commerce growth we've seen since 2021, and delivered our seventh consecutive quarter of accelerating active customer growth," shared Co-Founder and Co-CEO Neil Blumenthal. "Looking to the rest of the year, we'll leverage our diversified suppl

      5/8/25 6:45:00 AM ET
      $WRBY
      Ophthalmic Goods
      Health Care
    • Warby Parker to Announce First Quarter 2025 Financial Results on May 8, 2025

      Warby Parker Inc. (NYSE:WRBY) (the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the first quarter ended March 31, 2025 will be released before market open on May 8, 2025. In addition, the Company will discuss its results and business outlook during a live conference call and webcast at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 833-470-1428 from the U.S. or 404-975-4839 from international locations. The conference passcode is 020310. A live webcast of the conference call will be available on the investors section of the Company's website at investors.warbyparker.com where presentation

      4/17/25 4:05:00 PM ET
      $WRBY
      Ophthalmic Goods
      Health Care